USPTO Grants Universal Display US Patent for New Family of Phosphorescent Emitters

Universal Display Corporation, enabling energy-efficient displays and lighting with its Universal PHOLED® technology and materials, announced today that the United States Patent and Trademark Office (USPTO) has granted Universal Display its 2,000th patent, U.S. Patent No. 9,231,218 (the '218 Patent) for a new family of “Phosphorescent Emitters”.

Additionally, UDC’s 2,001st patent was issued on the same day, U.S. Patent No. 9,231,227 (the '227 Patent) for a novel “OLED Display Architecture”.

“As a leading OLED innovator with 20 plus years of technology and phosphorescent material know-how and experience, we are proud of the fundamental technology we continue to develop and commercialize to enable the OLED industry. The issuance of the '218 and ‘227 Patents adds to our vast and growing global OLED IP portfolio,” said Steven V. Abramson, President and Chief Executive Officer of Universal Display. “As a company, we are constantly driving invention at both the architectural and molecular levels. We believe these efforts are expanding and extending the lifetime of our core competencies well into the foreseeable future, while further strengthening our position as a key partner in the OLED ecosystem.”

Universal Display Corporation’s OLED IP portfolio consists of an extensive and robust suite of enabling state-of-the-art OLED technologies and currently includes more than 3,600 patents (2,000+ issued and 1,600+ pending) worldwide, including the U.S., Europe, Japan, Korea, Taiwan, China, India, Australia, Brazil, and Israel. The Company believes that these patents affirm the novel nature of the innovative research undertaken over the last two decades and the progression of significant technology advancements that will continue to bolster two of its key business segments, OLED material sales and OLED device licensing.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.